Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. develops and commercializes soft-tissue reconstruction solutions for surgeons, with a focus on products designed to preserve and restore patient anatomy while limiting long-term exposure to permanent synthetic materials. Its OviTex portfolio includes configurations used in hernia repair and abdominal wall reconstruction, including ventral, inguinal and hiatal procedures.
Company news commonly covers quarterly and annual results, revenue guidance, commercial execution, product portfolio updates, credit and capital actions, board and leadership changes, and equity compensation grants made under Nasdaq inducement-grant rules.
TELA Bio (NASDAQ: TELA) approved inducement equity grants for its newly hired CEO, Heather Getz, and 11 new employees under Nasdaq Listing Rule 5635(c)(4). Ms. Getz received stock options to purchase an aggregate 2,370,000 shares and restricted stock units (RSUs) covering 500,000 shares, granted on August 3, 2026.
The options include 1,365,000 “Standard Options” with a $0.74 exercise price and 1,005,000 “Premium-Options” at $0.90, each with a ten-year term and four-year vesting. The Compensation Committee also granted RSUs covering 95,500 shares to 11 new hires on August 4, 2026, with all RSUs vesting annually over four years, subject to continued service.
TELA Bio (NASDAQ: TELA) announced that its Board of Directors has appointed Heather Getz as Chief Executive Officer and Director, effective August 4, 2026. Chairman Joseph Capper said the Board selected Getz to guide TELA Bio’s next phase of growth, commercial execution and value creation for patients, surgeons, shareholders and employees.
According to TELA Bio, Getz most recently served as Executive Vice President and Chief Financial and Operations Officer at Butterfly Network (NYSE: BFLY), where she implemented strategic, capital allocation and cash runway changes. Previously, as Executive Vice President and Chief Financial and Administrative Officer at BioTelemetry, the company’s market capitalization increased from $50 million to $2.8 billion before its acquisition by Philips Healthcare in 2021. TELA Bio expressed gratitude to co‑founder and outgoing leader Antony Koblish for developing OviTex and helping establish its position in soft‑tissue reconstruction.
TELA Bio (NASDAQ: TELA) announced it will participate in the Canaccord Genuity 46th Annual Growth Conference. Company management is scheduled to present at 8:30 a.m. ET on August 12, 2026. A live and archived webcast of the presentation will be available at ir.telabio.com.
TELA Bio (NASDAQ: TELA) announced it will release its second quarter 2026 financial results on Monday, August 10, 2026. Management will host a conference call and webcast at 4:30 p.m. ET the same day to review the results and provide a corporate update.
Investors must register online to join the call, either a day in advance or at least 15 minutes before the start. A live webcast and subsequent replay will be available through the Events & Presentations page in the investor section of TELA Bio's website.
TELA Bio (NASDAQ: TELA) reported first quarter 2026 revenue of $19.1 million, up 3% year over year with 13% unit growth. European revenue grew 41%.
Gross margin was 65.7%, net loss was $12.3 million, cash was $39.5 million. Guidance calls for at least 8% 2026 revenue growth and about $20.0 million Q2 revenue.
TELA Bio (NASDAQ: TELA) announced inducement restricted stock unit grants covering 89,250 shares to 12 newly hired employees, with a grant date of May 5, 2026. The RSUs vest in equal annual installments over four years, subject to continued service through each vesting date.
TELA Bio (NASDAQ: TELA) announced a board refresh: four current directors will step down after the 2026 Annual Meeting on June 9, 2026, and four new commercial and finance leaders will join the Board, with Joseph Capper expected to be Chair if elected.
The company reported preliminary Q1 2026 revenue of ~$19.0 million versus prior guidance of ~$18.5 million; final results will be released May 12, 2026.
TELA Bio (NASDAQ: TELA) will report first quarter 2026 financial results on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a corporate update.
Investors must register online to join the call, registering at least one day in advance or at minimum 15 minutes before the start; a live webcast and replay will be available on TELA's investor Events & Presentations page.
TELA Bio (NASDAQ:TELA) reported Q4 2025 revenue of $20.9M (+18% YoY) and full-year 2025 revenue of $80.3M (+16% YoY). Q4 gross margin improved to 65.9%. Full-year net loss was $38.8M and cash totaled $50.8M. The company closed a $70.0M credit facility (initial $60.0M). Management projects at least 8% revenue growth in 2026 and Q1 2026 revenue of ~$18.5M.
Highlights include expanded commercial field coverage (≈88–89 reps) and promotion of Howard Langstein to Chief Medical Officer.
TELA Bio (NASDAQ: TELA) will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026.
Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a corporate update. Investors must register at least one day ahead or 15 minutes before the call. A live webcast and replay will be available on TELA's investor Events & Presentations page.